BMJ Open  Cost-effectiveness of integrated COPD care: the RECODE cluster randomised trial

Melinde R S Boland,1,2 Annemarije L Kruis,3 Apostolos Tsiachristas,1,2,4 Willem J J Assendelft,5 Jacobijn Gussekloo,3 Coert M G Blom,6 Niels H Chavannes,3 Maureen P M H Rutten-van Mölken1,2


ABSTRACT

Objectives: To investigate the cost-effectiveness of a chronic obstructive pulmonary disease (COPD) disease management (COPD-DM) programme in primary care, called RECODE, compared to usual care.

Design: A 2-year cluster-randomised controlled trial.

Setting: 40 general practices in the western part of the Netherlands.

Participants: 1086 patients with COPD according to GOLD (Global Initiative for COPD) criteria. Exclusion criteria were terminal illness, cognitive impairment, alcohol or drug misuse and inability to fill in Dutch questionnaires. Practices were included if they were willing to create a multidisciplinary COPD team.

Interventions: A multidisciplinary team of caregivers was trained in motivational interviewing, setting up individual care plans, exacerbation management, implementing clinical guidelines and redesigning the care process. In addition, clinical decision-making was supported by feedback reports provided by an ICT programme.

Main outcome measures: We investigated the impact on health outcomes (quality-adjusted life years (QALYs), Clinical COPD Questionnaire, St. George Respiratory Questionnaire and exacerbations) and costs (healthcare and societal perspective).

Results: The intervention costs were €324 per patient. Excluding these costs, the intervention group had €584 (95% CI €86 to €1046) higher healthcare costs than the usual care group and €645 (95% CI €28 to €1190) higher costs from the societal perspective. Health outcomes were similar in both groups, except for 0.04 (95% CI −0.07 to −0.01) less QALYs in the intervention group.

Conclusions: This integrated care programme for patients with COPD that mainly included professionally directed interventions was not cost-effective in primary care.

Trial registration number: Netherlands Trial Register NTR2268.

INTRODUCTION

Disease management programmes for chronic obstructive pulmonary disease (hereafter referred to as COPD-DM) have been developed to change COPD care from acute, reactive and one-size-fits-all into integrated, proactive and tailor-made. To stimulate the implementation of such programmes in the Netherlands, a new payment policy (ie, bundled payment) was recently implemented.1 However, the wide implementation of these programmes in the Netherlands, as is currently ongoing, would benefit by a justification from a cost-effectiveness perspective.

Recent systematic literature reviews of COPD-DM programmes showed favourable effects on both health outcomes and costs (mainly due to decreased hospitalisation).2 3 However, previous economic studies had poor methodological quality.2 4 Most studies did not measure all relevant costs and health outcomes and did not perform incremental cost-effectiveness analyses.2 For instance, there is little knowledge on the required investments in implementation of these programmes. Furthermore, the generalisability of the outcomes of these studies was low, due...
to the inclusion of patients with mainly severe COPD and the exclusion of patients with multimorbidity.256

We aimed to conduct a comprehensive cost-effectiveness analysis (CEA) of a COPD-DM programme in primary care compared to usual care in the Netherlands. This CEA was performed as part of a 2-year cluster randomised controlled trial (RCT) evaluating the clinical effects of this RECODE programme (acronym for Randomised clinical trial on Effectiveness of integrated COPD management in primary care).78

In the clinical paper we concluded that, after 12 months, the RECODE programme did not significantly improve the score on the Clinical COPD Questionnaire (CCQ) compared to usual care, despite an improved level of integrated care and a higher degree of self-reported physical activity.7 Our current paper includes additional outcome measures not reported in the clinical paper and it reports 24-month results. This is important because it is often argued that it takes time before the effect of DM programmes becomes clearly visible. The added value of a cost-effectiveness analysis is that we report the joint uncertainty in effects and costs, allowing us to report the probability that the RECODE programme would be cost-effective at various threshold values of the maximum acceptable costs per quality-adjusted life year (QALY) gained. Moreover, the publication of results in terms of cost-effectiveness is important to avoid selective reporting of positive studies. The published evidence is used to inform all decisionmakers across developed countries about whether and which COPD-DM programmes to reimburse on a wider scale.

METHODS
This study was approved by the medical ethics committee, performed according to the study protocol,8 as well as national9 and international10 guidelines for pharmacoeconomic research, and reported according to the Consolidated Health Economic Evaluation Reporting Standard (CHEERS).11

Design and intervention
RECODE is a 2-year cluster randomised trial in which 40 clusters of primary care teams were randomised to the COPD-DM programme or usual care. The 20 teams of the intervention group were trained in essential components of effective COPD-DM: proper diagnosis, optimising medication adherence, motivational interviewing, smoking cessation counselling, applying self-management plans including early recognition and treatment of exacerbations, physical (re)activation and nutritional support. In addition, the teams learnt the details of a web-based computer program for measuring and reporting process and outcome performance indicators, named ZORGDRAAD. This Information and Communications Technologies (ICT) application included a patient and provider portal that facilitated the communication within the multidisciplinary teams as well as between care providers and patients. At the end of the 2-day course, each team developed a plan with steps to be taken in order to redesign the care process and integrate the COPD-DM programme into their daily practice. After the course, the teams were invited to join refresher courses, received regular feedback reports on patients’ outcomes and had access to ZORGDRAAD. The local healthcare insurer reimbursed physical reactivation for patients with a Medical Research Council (MRC) dyspnoea score >2, and also if these patients had no supplementary insurance. All practices were flexible in determining and following their individual plans. Therefore, the mix and intensity of interventions for individual patients depended on their health status, personal needs and preferences, as well as the actions taken by the team. Healthcare providers in the usual care group were asked to continue providing care as usual. The care as usual has been reported previously.8

Target population
The enrolment of primary care teams and their patients with COPD took place between September 2010 and September 2011. Participating teams included at least one general practitioner (GP), one practice nurse and one physiotherapist. Patients had physician-diagnosed COPD according to GOLD guidelines.12 Exclusion criteria were terminal illnesses, dementia, cognitive impairment, inability to complete questionnaires in Dutch and hard drug or alcohol abuse. Other comorbidity was not an exclusion criterion. The GPs verified that the included patients fulfilled the inclusion and exclusion criteria. All participating GPs and patients with COPD provided written informed consent before participation.

Outcomes
Costs were related to the following outcome measures:
1. QALYs based on the EuroQol-5D (EQ-5D) utility values using the Dutch value set;1314
2. Proportion of patients with a minimal clinical important difference (MCID) (ie, improvement ≥0.4) on the CCQ.1516
3. Proportion of patients with an MCID (ie, improvement ≥4) on St. George’s Respiratory Questionnaire (SGRQ);1718
4. Total number of COPD exacerbations (moderate and severe). A moderate exacerbation was defined as a worsening of daily symptoms that led a patient’s clinician to prescribe systemic corticosteroids and/or antibiotics, but did not require hospitalisation. This information was extracted from the Electronic Medical Records (EMR). A severe exacerbation was defined as a worsening of symptoms that required a hospital admission. Hospital admissions were obtained from the resource use questionnaires and the EMR.
The EQ-5D, CCQ, SGRQ and resource use questionnaires were administered at baseline and at 6, 9, 12, 18 and 24 months.

Costs
Total 2-year costs (not only those related to COPD) were calculated from a healthcare perspective and a societal perspective. The healthcare perspective included all costs covered by the healthcare budget, that is, medication prescriptions, contact with care providers (GP, medical specialist, nurse, physiotherapist, dietitian, podiatrist, occupational therapist), home care, hospital admissions, emergency department visits and pulmonary rehabilitation. The costs from the societal perspective additionally included travel costs and costs of productivity loss due to absence from paid work.

Patients reported the healthcare utilisation (excluding medication), travel costs, days of absence from paid work due to illness (absenteeism) and lost productivity while being at work (presenteeism) in a resource use questionnaire with a recall period of 3 months.

The medication prescriptions were extracted from the EMRs of the GPs. Standard unit costs were obtained from the Dutch manual for costing research and inflated to 2013 using the general consumer price index. The costs of medications were obtained from the GIP-Databank and included value added tax and pharmacist dispensing fees. The productivity costs were estimated using the Friction Cost Approach, which assumes that productivity loss occurs as long as a sick employee is not replaced (the friction period). We used a friction period of 115 days, that is, the average duration of vacancies (87 days) increased with the expected number of weeks employers need before taking the decision to place a vacancy for temporary or permanent replacement of the worker (28 days).

The intervention costs, defined as costs of training the teams, costs of the ICT support and costs of the monitoring reports, were calculated on the basis of course attendance (initial 2-day course and refresher courses), computer-documented ICT-use and time involved in producing monitoring reports (for each practice, the estimated labour time was 2.5, 0.5 and 1 h to produce the reports at baseline and at 6 months and 12 months, respectively).

Statistical analysis
Data analysis was performed according to the intention-to-treat principle. Data from patients who discontinued the trial prematurely were included in the analysis up to the point of dropout. Additionally, patients who dropped out during the first year were asked to fill in a CCQ questionnaire at 12 months, if possible.

We used repeated measures models to assess differences between RECODE and usual care, correcting for time, age, gender, MRC dyspnoea score ≥2, baseline score and clustering of patients. The distribution and link function for each outcome was selected after comparing the goodness-of-fit of models with different specifications of the distribution and link functions. Models that had the lowest Akaike’s Information Criterion were selected.

EQ-5D utilities were analysed using linear mixed models with a normal distribution and identity link. We calculated the number of QALYs for each patient as the area under the predicted utility curve, using linear interpolation between two utility measurements. Generalised linear mixed models with a binary distribution and logit link were used to analyse the proportion of patients with an MCID on the CCQ and SGRQ questionnaires. The differences in exacerbation rates were estimated using generalised linear mixed models with negative binomial distribution and log link. Costs were analysed with generalised linear mixed models using a log-normal distribution and identity link. The cost estimate for months 5–6 (based on the questionnaire administered in month 6) was linearly extrapolated to include months 0–3.

The same was carried out for the cost estimate of months 15–18 and 21–24.

Cost-effectiveness
Cost-effectiveness was reported in terms of costs per QALY. Additionally, the following incremental cost-effectiveness ratios (ICERs) were calculated: costs per additional patient with an MCID on the CCQ, costs per additional patient with an MCID on the SGRQ and costs per exacerbation prevented. Taking a multioutcome approach is in line with recent guidelines.

Uncertainty around the ICERs was handled by bootstrapping the data 5000 times. Bootstrapping means repeatedly drawing samples with replacement from the original data set. Each sample has the same size as the trial and for each sample the difference in costs and QALYs between RECODE and usual care and the ICER is calculated. The 2.5th and the 97.5th centile of the 5000 bootstrap replications form the 95% uncertainty interval of the differences in costs and QALYs. The 5000 ICERs were plotted on cost-effectiveness planes. In a cost-effectiveness plane, the horizontal axis displays the difference in effects and the vertical axis displays the difference in costs. The results of the bootstrap replications can fall into one of four quadrants: north-east quadrant (more cost and more effects); north-west quadrant (less cost and more effects); south-east quadrant (less cost and less effects); south-west quadrant (more cost and less effects; see online supplementary appendix 1). Finally, the probability that the RECODE programme is cost-effective using different thresholds for the monetary value of a QALY was shown in cost-effectiveness acceptability curves. This probability equals the proportion of bootstrap replications in which the ICER is lower than the threshold value.

Sensitivity and subgroup analyses
Two sensitivity analyses were performed: one with the inclusion of intervention costs and the other with a
RESULTS

Patients

The flow chart of patient inclusion has been presented elsewhere. In total, we included 1086 patients with COPD from 40 teams in the trial, 554 in the RECODE group and 532 in the usual care group. The baseline characteristics of the patients in the RECODE and usual care groups are summarised in table 1. The only statistically significant difference was a higher percentage of males in the usual care group (51 vs 57%).

The proportion of patients who completed the trial was 76% in the RECODE group and 74% in the usual care group. Length of follow-up among the dropouts was not significantly different between groups, with a mean (±sd) follow-up of 20.5 (±0.29) and 20.0 (±0.33) months, respectively. Patients who dropped out were significantly older and had a significantly worse baseline score on the CCQ, SGRQ, MRC-dyspnoea and EQ-5D. Baseline characteristics between the dropouts of the RECODE group and the usual care group were not significantly different.

Costs

The intervention costs are presented in table 2. The total intervention costs per patient ranged from €103 to €587 across clusters, with a mean (±sd) of €324 (±156) per patient. This variation is explained by the number of patients with COPD per team, the use of the ICT system, the number of healthcare providers participating in the courses and the different locations of the courses. The labour costs of the attendees of the RECODE courses were the main driver of the intervention costs (54%).

Complete 2-year medication data of 500 patients (90%) in the RECODE group and 478 patients (90%) in the usual care group were extracted from the EMRs. More than 85% of the participants used medication for obstructive airway diseases in the 2-year trial period (table 3).

Of the 1086 patients, 93% had complete healthcare utilisation data at 6 months, 79% at 9 months, 88% at 12 months, 73% at 18 months and 75% at 24 months. This was similar for both groups. The unit costs, observed mean use of resources and associated costs, as reported by the patients, are presented in table 3. In both groups, important cost drivers were hospital admissions, home care and productivity loss. Excluding intervention costs, the adjusted mean total 2-year costs (estimated from the generalised linear mixed model) were significantly higher in the RECODE group than in the usual care group by €584 from the healthcare perspective and €645 from the societal perspective (table 4).

Outcomes

Over a 2-year period, the number of QALYs was 0.04 (p=0.02) lower in the RECODE group than in the usual care group while there was no significant difference in the percentage of patients with an MCID on the CCQ, nor in any of the other outcomes (table 4).

Cost-effectiveness

From a healthcare and societal perspective, the point estimates of costs and effects pointed towards higher costs and lower effects of the RECODE programme, resulting in negative ICERs for all outcome measures (QALYs, exacerbation avoided, additional patient with an MCID on the CCQ score, and additional patient with an MCID on the SGRQ score). The CE planes of the different outcomes showed that the majority of the bootstrap replications (>98%) had higher costs. Furthermore, more than half of the bootstrap replications fell within the north-west quadrant of the plane indicating that RECODE was dominated by the usual care group, for example, more costs and less effects.

Sensitivity analyses

When including the intervention costs, the cost difference, which favoured usual care, further increased to a

Table 1 Baseline characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>RECODE (n=554)</th>
<th>Usual care (n=532)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (SD)</td>
<td>68.2±11.3</td>
<td>68.4±11.1</td>
</tr>
<tr>
<td>Male sex (%)</td>
<td>50.5</td>
<td>57.3*</td>
</tr>
<tr>
<td>Employment (%)</td>
<td>27.7</td>
<td>28.8</td>
</tr>
<tr>
<td>Low education/low social</td>
<td>39.2</td>
<td>41.5</td>
</tr>
<tr>
<td>economic status (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marital status: single (%)</td>
<td>37.0</td>
<td>38.3</td>
</tr>
<tr>
<td>FEV1% predicted, mean (SD)</td>
<td>67.7 (20.3)</td>
<td>67.9 (20.5)</td>
</tr>
<tr>
<td>Current smoker (%)</td>
<td>34.8</td>
<td>38.7</td>
</tr>
<tr>
<td>Former smoker (%)</td>
<td>53.8</td>
<td>52.6</td>
</tr>
<tr>
<td>Moderate exacerbation in the past year, mean (SD)</td>
<td>0.36 (0.83)</td>
<td>0.33 (0.78)</td>
</tr>
<tr>
<td>Severe exacerbation in the past 3 months, mean (SD)</td>
<td>0.02 (0.18)</td>
<td>0.02 (0.17)</td>
</tr>
<tr>
<td>Charlson comorbidity index</td>
<td>2.35 (1.26)</td>
<td>2.32 (1.27)</td>
</tr>
<tr>
<td>Major cardiovascular disease (%)</td>
<td>14.6</td>
<td>17.7</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>35.4</td>
<td>38.3</td>
</tr>
<tr>
<td>Diabetes (%)</td>
<td>14.6</td>
<td>14.8</td>
</tr>
<tr>
<td>Depression (%)</td>
<td>9.8</td>
<td>10.1</td>
</tr>
<tr>
<td>MRC score, mean (SD)</td>
<td>2.06 (1.30)</td>
<td>1.95 (1.26)</td>
</tr>
<tr>
<td>MRC score &gt;2 (%)</td>
<td>35.1</td>
<td>31.6</td>
</tr>
<tr>
<td>CCQ score, mean (SD)</td>
<td>1.54 (0.98)</td>
<td>1.46 (0.96)</td>
</tr>
<tr>
<td>SGRQ total score, mean (SD)</td>
<td>36.7 (21.1)</td>
<td>34.5 (19.8)</td>
</tr>
<tr>
<td>EQ-5D score, mean (SD)</td>
<td>0.74 (0.25)</td>
<td>0.73 (0.28)</td>
</tr>
</tbody>
</table>

*Significant (p<0.05).

FEV1, forced expiratory volume in 1 s; MRC, Medical Research Council; CCQ, Clinical COPD Questionnaire; SGRQ, St. George’s Respiratory Questionnaire; EQ-5D, EuroQoL-5D.
difference of €883 from the healthcare perspective and €1005 from the societal perspective (see online supplementary appendix 2).

Using a 12-month instead of a 24-month time horizon, the costs per patient were significantly higher in the RECODE group in comparison with the usual care group by €408 from the healthcare perspective and €370 from the societal perspective (see online supplementary appendix 3). After 12 months, there was no significant difference in QALYs, or any of the other outcomes, except for the percentage of patients improving at least the MCID on the CCQ, which was 7% less in the RECODE group than in the usual care group. After 12 months, the costs per QALY ratio of RECODE compared to usual care was €38 471 from a healthcare perspective and €42 458 from a societal perspective.

The probability that RECODE is cost-effective at a willingness-to-pay of €20 000 and €80 000 per QALY at 12 months was 8% and 79%, respectively (see online supplementary appendix 4). It is more likely that RECODE is cost-effective within the subgroup of patients <65 years.

**DISCUSSION**

This study compared the costs and health effects of a COPD-DM programme in primary care (RECODE) with usual care in the Netherlands. Our results show that RECODE is not cost-effective from a healthcare as well as a societal perspective. The point estimates of costs and effects pointed towards higher costs and no significant difference in QALYs between RECODE and usual care, whereas in patients 65 or over there were fewer QALYs in RECODE than in usual care (see online supplementary appendix 4). It is more likely that RECODE is cost-effective within the subgroup of patients <65 years.

Subgroup analyses

Only age showed a significant interaction with the effect of RECODE on costs (see online supplementary appendix 5 and 6). The difference in costs (healthcare and societal perspective) between RECODE and usual care was significantly lower in patients younger than 65 years than in patients above 65 years. There was also a significant interaction between age and the effect of RECODE in terms of QALYs. In patients below 65, there was no significant difference in QALYs between RECODE and usual care, whereas in patients 65 or over there were fewer QALYs in RECODE than in usual care (see online supplementary appendix 4). It is more likely that RECODE is cost-effective within the subgroup of patients <65 years.

<table>
<thead>
<tr>
<th>Table 2 Intervention costs (in €, 2013)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DM intervention cost description</td>
</tr>
<tr>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>RECODE Course</td>
</tr>
<tr>
<td>Catering</td>
</tr>
<tr>
<td>Location</td>
</tr>
<tr>
<td>Presenters</td>
</tr>
<tr>
<td>Other costs*</td>
</tr>
<tr>
<td>Labour costs of replacement course participants</td>
</tr>
<tr>
<td>Travel</td>
</tr>
<tr>
<td>Refresher course</td>
</tr>
<tr>
<td>Catering</td>
</tr>
<tr>
<td>Location</td>
</tr>
<tr>
<td>Presenters</td>
</tr>
<tr>
<td>Other costs*</td>
</tr>
<tr>
<td>Labour costs attendees</td>
</tr>
<tr>
<td>Travel</td>
</tr>
<tr>
<td>ICT system ZORGDRAAD</td>
</tr>
<tr>
<td>Labour costs of ICT use</td>
</tr>
<tr>
<td>Labour costs of ICT support</td>
</tr>
<tr>
<td>Monitoring reports</td>
</tr>
<tr>
<td>Labour costs of feedback report at baseline</td>
</tr>
<tr>
<td>Labour costs of feedback report at 6 months</td>
</tr>
<tr>
<td>Labour costs of feedback report at 12 months</td>
</tr>
<tr>
<td>Total</td>
</tr>
</tbody>
</table>

*Other costs include material and equipment used during the course.

DM, disease management; ICT, information and communications technologies.
To avoid contamination, randomisation was performed at the cluster level. Since blinding of participants and clinicians was impossible, blinded research nurses collected the data, while patients were instructed not to report back on their type of intervention. Additional strengths of this study are the 2-year follow-up period, the broad range of health outcomes and cost categories included and the sophisticated analyses that took into account the hierarchical nature of the data. A limitation of our study is that we collected healthcare resource utilisation at baseline and at 6, 12, 18 and 24 months using a questionnaire with a 3-month recall period, necessitating the extrapolation of the 3-month data to 6 months to estimate the costs of months 3–6, 15–18 and 21–24. We chose to collect intermittent data for two reasons. The first was to avoid study dropouts resulting from endless questionnaires or daily diaries over a long follow-up period. The second reason was that evidence from the literature suggests that intermittent data provide reliable estimates of total annual health expenditures.23 A second limitation is that patients who dropped out were significantly older and had a significantly worse baseline score on the CCQ, SGRQ, MRC-dyspnoea and EQ-5D, thus potentially jeopardising the generalisability of the results. However, baseline characteristics of the dropouts in the RECODE group and the dropouts in the usual care group were not significantly different. Moreover, after correction for baseline scores, no evidence of benefits of the intervention were found, indicating that dropouts are unlikely to have biased the results.

There are several possible explanations for the finding that the RECODE intervention was not cost-effective. First, it may be due to the relatively low intensity of our pragmatic intervention. The RECODE programme did not require the teams to implement all elements of effective COPD-DM that they learnt during the courses. Instead, each team made their own plan to redesign the care process and implement COPD-DM. Consequently, the mixture and intensity of interventions for individual patients was dependent on the health status, personal needs and preferences of the individual patients, as well as on the specific focus that a team may have chosen.

### Table 3

Unit costs, data sources, mean use of resources and associated costs over the 2 years, as reported by the patients (unadjusted)

<table>
<thead>
<tr>
<th>Costs from a healthcare perspective</th>
<th>RECODE</th>
<th>Usual care</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GP, (home) visits, phone contacts</strong></td>
<td>Any use (%)</td>
<td>Mean use</td>
</tr>
<tr>
<td>GP, (home) visits</td>
<td>91</td>
<td>16.23</td>
</tr>
<tr>
<td>Practice nurse, visits</td>
<td>74</td>
<td>5.51</td>
</tr>
<tr>
<td>Specialist, visits</td>
<td>78</td>
<td>10.05</td>
</tr>
<tr>
<td>Emergency department, visits</td>
<td>26</td>
<td>0.78</td>
</tr>
<tr>
<td>Physiotherapist, visits</td>
<td>53</td>
<td>25.82</td>
</tr>
<tr>
<td>Dietician, visits</td>
<td>21</td>
<td>1.45</td>
</tr>
<tr>
<td>Podiatrist, visits</td>
<td>43</td>
<td>3.78</td>
</tr>
<tr>
<td>Speech therapist, visits</td>
<td>3</td>
<td>0.12</td>
</tr>
<tr>
<td>Occupational therapy, visits</td>
<td>4</td>
<td>0.29</td>
</tr>
<tr>
<td>Rehabilitation centre, visits</td>
<td>12</td>
<td>3.86</td>
</tr>
<tr>
<td>Home care, hours of household help</td>
<td>22</td>
<td>34.42</td>
</tr>
<tr>
<td>Home care, hours of personal care</td>
<td>9</td>
<td>8.28</td>
</tr>
<tr>
<td>Home care, hours of nursing</td>
<td>6</td>
<td>2.11</td>
</tr>
<tr>
<td>Home care, other, hours</td>
<td>1</td>
<td>0.47</td>
</tr>
<tr>
<td>Hospital stay, days</td>
<td>25</td>
<td>4.65</td>
</tr>
<tr>
<td>Intensive care unit, days</td>
<td>5</td>
<td>0.49</td>
</tr>
<tr>
<td>Drugs for obstructive airway diseases</td>
<td>84</td>
<td>945±814</td>
</tr>
<tr>
<td>Other medication</td>
<td>91</td>
<td>1367±3421</td>
</tr>
<tr>
<td><strong>Costs from a societal perspective</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Travel expenses, public transport/car, km</td>
<td>94</td>
<td>189.00</td>
</tr>
<tr>
<td>Productivity loss, absenteeism hours</td>
<td>11</td>
<td>47.74</td>
</tr>
<tr>
<td>Productivity loss, presenteeism hours</td>
<td>8</td>
<td>10.38</td>
</tr>
</tbody>
</table>

*Sources of unit costs used in the analysis: (1) Dutch guidelines for pharmacoeconomic research,9 (2) The Dutch Healthcare Authority NZA (3) GIP Databank.20
## Costs and Effectiveness Analyses from the Base Case (€, 2013)

<table>
<thead>
<tr>
<th>Effect</th>
<th>Cost per QALY HP</th>
<th>Cost per exacerbation avoided HP</th>
<th>Cost per additional patient with a clinical relevant improvement in the CCQ score</th>
<th>Cost per additional patient with a clinical relevant improvement in the SGRQ score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Usual care</td>
<td>5.119</td>
<td>4.535</td>
<td>584* (86 to 1046)</td>
<td>0.11</td>
</tr>
<tr>
<td>RECODE care</td>
<td>5.119</td>
<td>4.535</td>
<td>584* (86 to 1046)</td>
<td>0.11</td>
</tr>
</tbody>
</table>

### Table 4

Results from the cost-utility and cost-effectiveness analyses from the base case (€, 2013)

- **Usual care**:
  - **Cost per QALY**: €5.119
  - **Cost per exacerbation avoided**: €4.535
  - **Cost per additional patient with a clinical relevant improvement in the CCQ score**: €584* (86 to 1046)

- **RECODE care**:
  - **Cost per QALY**: €5.119
  - **Cost per exacerbation avoided**: €4.535
  - **Cost per additional patient with a clinical relevant improvement in the CCQ score**: €584* (86 to 1046)

### Notes

- Significant (p<0.05).
- *Significant (p<0.05).
- Costs Effect Cost-effectiveness planes
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECODE
- Usual care Difference (95% CI) RECOD
Fourth, changes in healthcare occurred during the study period that affected COPD care in the RECODE as well as the usual care group. Since July 2010, a new bundled payment scheme for patients with COPD has been introduced in the Netherlands to stimulate the integration of care. In this scheme, healthcare insurers purchase integrated care from care groups by negotiating a fixed price per patient per year for all multidisciplinary COPD care required by a patient. As the bundle excludes secondary care and medications, it primarily stimulates the cooperation between different providers in the primary care setting. This increased attention for integrated chronic care and the ability to reimburse COPD interventions such as smoking cessation and nutritional counselling could have stimulated integrated care in the usual care group too.

Future research should determine the cost-effectiveness of more intensive COPD-DM programmes in primary care using a long(er) time horizon. Hence, the gains from preventing patients with moderate COPD to progress to severe COPD are likely to be detected only in the long run.

In conclusion, this comprehensive economic evaluation of an integrated care programme in primary care showed that the programme increased costs but did not improve health outcomes. It even reduced QALYs. This is most likely due to the suboptimal translation of the provider-oriented interventions of the RECODE programme into patient-oriented interventions, the suboptimal implementation of the interventions, the relatively mild COPD population and the national reforms in COPD care.

Author affiliations
1 Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands
2 Institute of Health Policy and Management, Erasmus University, Rotterdam, The Netherlands
3 Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands
4 Department of Population Health, Health Economics Research Centre, University of Oxford, Oxford, UK
5 Department of Primary and Community Care, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
6 Stichting Zorgdraad foundation, Oosterbeek, The Netherlands
7 College voor Zorgverzekeringen, 2010.
8 College voor Zorgverzekeringen, 2010.
9 College voor Zorgverzekeringen, 2010.

Contributors
MPMHR-vM, WJJA, JG and NHC conceived and designed the study. MRSB, ALK, AT and CMGB acquired the data. MRSB, AT and MPMHR-vM analysed and interpreted the data. MRSB drafted the manuscript. ALK, NHC, AT, JG, WJJA and MPMHR-vM advised on the preparation of the manuscript. All authors read, edited and approved the final version of the manuscript.

Funding
This paper presents independent research funded by Stichting Achmea Geszondheidszorg, a Dutch Healthcare insurance company and the Netherlands Organisation for Health Research and Development (Zon-MW) (project number 171002203). The funding agencies (Zon-MW and Achmea Zorgverzekeringen) had no influence on the design of the study, the analysis, or the writing of the paper. Throughout the RECODE intervention period, physiotherapists in the intervention group received supplementary funding for providing a COPD specific exercise training programme in patients with MRC scores >2. This fund is provided by two local Dutch healthcare insurers: “Centraal Ziektenfonds (CZ) Zorgverzekerings” and “Zorg en Zekerheid.” All other components of the integrated disease management programme were financially covered by the patients’ basic insurance scheme.

Competing interests None declared.

Patient consent Obtained.

Ethics approval The study was reviewed and approved by the medical ethical committee of the Leiden University Medical Centre, the Netherlands.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


